fexofenadine (OTC)

Brand and Other Names:Allegra, Allegra Allergy 12 Hour, more...Allegra Allergy 24 Hour, Children's Allegra Allergy, Mucinex Allergy
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablets

  • 30mg
  • 60mg
  • 180mg

oral suspension

  • 30mg/5mL

oral disintegrating tablets

  • 30mg
more...

Seasonal Allergic Rhinitis/Chronic Idiopathic Urticaria

180 mg PO qDay or 60 mg PO BID

Dosing Modifications

Renal impairment (CrCl <80 mL/min): 60 mg PO qDay initially

Administration

Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew

Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr

Dosage Forms & Strengths

tablets

  • 30mg
  • 60mg
  • 180mg

oral suspension

  • 30mg/5mL

oral disintegrating tablets

  • 30mg
more...

Seasonal Allergic Rhinitis

<2 years: Use not recommended

2-12 years: 30 mg PO BID

>12 years: 60 mg PO BID OR 180 mg PO qDay

Allegra ODT

  • 6-12 years: 30 mg PO BID

Chronic Idiopathic Urticaria

<6 months: Use not recommended

6 months-2 years: 15 mg PO BID

2-12 years: 30 mg PO BID

>12 years: 60 mg PO BID OR 180 mg PO qDay

Allegra ODT

  • 6-12 years: 30 mg PO BID

Dosing Modifications

Renal impairment (CrCl <80mL/min)

  • <6 months: Safety and efficacy not established
  • 6 months to 2 years: 15 mg PO qDay, initially
  • 2-12 years: 30 mg PO qDay, initially
  • >12 years: 60 mg PO qDay, initially

Administration

Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew

Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr

Next:

Interactions

Interaction Checker

and fexofenadine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Varies in incidence and severity with the individual drug; also, individual patients vary in susceptibility

            >10%

            Vomiting (6-12%)

            1-10%

            Headache (5-10%)

            Cough (4%)

            Diarrhea (3-4%)

            URTI (3%)

            Back pain (2-3%)

            Pyrexia (2%)

            Dysmenorrhea (2%)

            Dizziness (2%)

            Stomach discomfort (2%)

            Pain in extremity (2%)

            Somnolence (1-3%)

            Rhinorrhea (1-2%)

            Postmarketing Reports

            Sleep disorders (insomnia, paranoia)

            Nervousness

            Hypersensitivity reactions (anaphylaxis, urticaria, angioedema, chest tightness, dyspnea, flushing, pruritus, rash)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Allegra ODT contains phenylalanine

            Severe renal impairment

            Coadministration with fruit juice may decrease efficacy

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Excretion in milk unknown; use with caution (AAP states “compatible with nursing”)

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            H1 histamine receptor antagonist; competes for H1-receptor sites in target cells in the respiratory tract, blood vessels, and gastrointestinal tract; major metabolite of terfenadine

            Absorption

            Duration: ≥12 hr

            Peak serum time: 2-3 hr (tablet); 2 hr (ODT); 1 hr (suspension)

            Peak plasma concentration: 131 ng/mL

            Distribution

            Protein bound: 60-70%

            Metabolism

            Hepatic (5%)

            Elimination

            Half-life: 14.4 hr (31-72% longer in renal impairment)

            Excretion: Feces (80%), urine (11%)

            Previous
            Next:

            Images

            Previous
            Next: